ASAH1 and Fabry disease: In cases of FD patients with CNS manifestations, HSCT was found to elevate ACDase activity in peripheral blood leukocytes, resolve subcutaneous nodules, alleviate pain, and reduce hoarse voice but did not relieve neurological symptoms [71,92,117,118].